SCHEMBL2233946

SCHEMBL2233946

COC(=O)c1c(C=O)ncn1C(c1ccccc1)(c1ccccc1)c1ccccc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNN4 O15554 1/20 0.36
TSHR P16473 1/20 0.36
ALDH1A1 P00352 4/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
RAB9A P51151 2/20 0.34
MAPK1 P28482 1/20 0.34
NPC1 O15118 1/20 0.34
DAPK3 O43293 1/20 0.34
JAK2 O60674 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
ABL1 P00519 1/20 0.34
CSF1R P07333 1/20 0.34
RET P07949 1/20 0.34
MET P08581 1/20 0.34
PDGFRA P16234 1/20 0.34
PRKACA P17612 1/20 0.34
LTK P29376 1/20 0.34
GRK5 P34947 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2236527 0.82 KDM4E (0.40) KCNN4TSHRALDH1A1MEN1KMT2A
SCHEMBL312495 0.76 KDM4C (0.39) ALDH1A1MEN1KMT2AKDM4EMAPT
SCHEMBL17465811 0.74 GAA (0.51) TSHRALDH1A1KMT2AMAPK8KDM4E
SCHEMBL11332456 0.73 KCNN4 (0.42) KCNN4TSHRALDH1A1MEN1KMT2A
SCHEMBL9571783 0.72 LMNA (0.32) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL5357188 0.72 MAPT (0.42) KCNN4TSHRALDH1A1MEN1KMT2A
SCHEMBL21367852 0.71 ALDH1A1 (0.40) TSHRALDH1A1MEN1KMT2ARAB9A
SCHEMBL9571793 0.70 ALDH1A1 (0.32) KCNN4ALDH1A1MEN1KMT2AKDM4E
SCHEMBL2234725 0.70 ALDH1A1 (0.34) ALDH1A1MAPK1
SCHEMBL3070854 0.70 TSHR (0.42) TSHRALDH1A1MEN1KMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-01 US disclosed
EP-2361910-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY Taisho Pharmaceutical Co., Ltd. (JP) 2011-08-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110213143-A1 COMPOUND HAVING TAFIA INHIBITORY ACTIVITY TAF1, TAF5, TAF11 KCNN4 395/4885TSHR 48/4885ALDH1A1 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.